Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine add-on therapy in PLA2R-positive membranous nephropathy
ChiCTR2300076346Phase 4Completed
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of hydroxychloroquine in membranous glomerulonephritis (MGN) (2 arms), sponsored by Shengjing Hospital of China Medical University. Primary endpoint: Clinical remission rate. Started May 2020; status: completed.
02
Drugs
hydroxychloroquine
03
Conditions
membranous glomerulonephritis (MGN)
Beyond the preview
Go deeper on ChiCTR2300076346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076346.